U.S. markets closed

Syncona Ord (SYNC.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
121.00-3.40 (-2.73%)
At close: 04:45PM GMT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close124.40
Bid119.20 x 0
Ask121.40 x 0
Day's Range117.60 - 125.00
52 Week Range105.00 - 197.00
Avg. Volume876,257
Market Cap814.595M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateNov 16, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est240.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SYNC.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

      Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.

    • GlobeNewswire

      Syncona to Acquire Freeline Therapeutics

      Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing adva

    • BioPharma Dive

      Freeline, after cuts, agrees to take-private deal with Syncona

      The planned acquisition adds to a string of bargain buyouts and reverse mergers in the gene therapy field.